Peil Biomedical Subsidiary Receives NMPA Approval for Phase I Clinical Trial of RA Drug PP011 in China
NQ Score
83/100
N1 Content Completeness
5
Key facts
- Peil Biomedical Subsidiary Receives NMPA Approval for Phase I Clinical Trial of RA Drug PP011 in China
- Peil Biomedical announced that its wholly-owned subsidiary, Peil (Shanghai) Pharmaceutical Technology, has received approval from China's National Medical Products Administration (NMPA) to conduct Phase I clinical trials for its oral new drug PP011, intended for rheumatoid arthritis (RA). The trial is expected to be completed by Q1 2027.
- Source: TWSE
- Date: Tue Jun 02 2026 09:00:00 GMT+0900 (Japan Standard Time)
Direct answer
Peil Biomedical announced that its wholly-owned subsidiary, Peil (Shanghai) Pharmaceutical Technology, has received approval from China's National Medical Products Administration (NMPA) to conduct Phase I clinical trials for its oral new drug PP011, intended for rheumatoid arthritis (RA). The trial is expected to be completed by Q1 2027.
- Citation
- Peil Biomedical Subsidiary Receives NMPA Approval for Phase I Clinical Trial of RA Drug PP011 in China (Tue Jun 02 2026 09:00:00 GMT+0900 (Japan Standard Time)), TWSE
- Source
- TWSE
- Date
- Tue Jun 02 2026 09:00:00 GMT+0900 (Japan Standard Time)
AI Summary (NQ-processed)
Peil Biomedical announced that its wholly-owned subsidiary, Peil (Shanghai) Pharmaceutical Technology, has received approval from China's National Medical Products Administration (NMPA) to conduct Phase I clinical trials for its oral new drug PP011, intended for rheumatoid arthritis (RA). The trial is expected to be completed by Q1 2027.
AI Analysis
Frequently Asked Questions
- Q: What is Peil Biomedical's PP011?
- A: It is an oral new drug candidate for rheumatoid arthritis (RA).
- Q: What is the clinical trial status?
- A: Approved by China's NMPA for Phase I trials, expected to be completed in Q1 2027.
- Q: Why develop an oral drug?
- A: To address the inconvenience of current injectable biologics for RA treatment.